SINGAPORE, 14 APRIL 2022: Us2.ai, the Singapore-based medtech developers of FDA- cleared AI software that, for the first time ever, fully automates a complete echocardiography (heart ultrasound) report, today announced...
LipoScience Sets IPO Term
News | 01. 10. 2013
NEW YORK--LipoScience Inc. set terms for its initial public offering Thursday, with the diagnostics company looking to raise as much as $75 million and become the first health-care company to go public this year.
The company said in a filing with the Securities and Exchange Commission that it expects to fetch between $13 and $15 each for its five million shares.
The company develops medical diagnostic tests and analytics tools. Its key product measures low-density lipoprotein, or LDL, particles in blood. The particles can provide clues about heart disease.
